Loretta Jophlin is a Gastroenterology physician affiliated with University of Louisville. OpenAlex indexes 36 publications with 657 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4950 Norton Healthcare Blvd Ste 205
Louisville, KY 402412847
Telephone
502-896-4711Provider last certified this registry record 13 Oct 2025.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Salix Pharmaceuticals, a division of Bausch Health US, LLCProgram year20256 payments
- Mirum Pharmaceuticals, Inc.Program year20251 payment
- Salix Pharmaceuticals, a division of Bausch Health US, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.6%Calcineurin inhibitor27.8%Tacrolimus68%Envarsus Xr20%Cyclosporine Modified12%Part D<11 patientsKinase inhibitor11.9%Everolimus73%Sirolimus27%Part D<11 patientsMetabolism & gastrointestinal
26.7%Proton pump inhibitor7.1%Pantoprazole Sodium76%Omeprazole25%Part D<11 patientsCorticosteroid6.9%Prednisone100%Part D≥18 patients+ 4 more classes in this area
Cardiovascular
22.9%Beta blocker6.7%Carvedilol78%Metoprolol Tartrate22%Part D<11 patientsCalcium channel blocker6.1%Amlodipine Besylate100%Part D≥16 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2023 per NIH RePORTER. The latest:
- Interaction of the Microtubule Cytoskeleton and Perilipin-2 Regulates Hepatic Lipid Droplets - a Potential Therapeutic Target for Fatty Liver Disease
University of Louisville
FY2023$165,780K08DK123381 - Interaction of the Microtubule Cytoskeleton and Perilipin-2 Regulates Hepatic Lipid Droplets - a Potential Therapeutic Target for Fatty Liver Disease
University of Louisville
FY2022$165,780K08DK123381 - Interaction of the Microtubule Cytoskeleton and Perilipin-2 Regulates Hepatic Lipid Droplets - a Potential Therapeutic Target for Fatty Liver Disease
University of Louisville
FY2021$165,780K08DK123381
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Kelly McMasters, MD
University of Louisville
Stephen McClave, MD
University of Louisville
Robert Friedland, MD
University of Louisville
Charles Scoggins, MD
University of Louisville
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”